Standout Papers

Lebrikizumab Treatment in Adults with Asthma 2001 2026 2009 2017 1.1k
  1. Lebrikizumab Treatment in Adults with Asthma (2011)
    Jonathan Corren, Robert F. Lemanske et al. New England Journal of Medicine
  2. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma (2001)
    William W. Busse, Jonathan Corren et al. Journal of Allergy and Clinical Immunology
  3. Tezepelumab in Adults with Uncontrolled Asthma (2017)
    Jonathan Corren, Jane R. Parnes et al. New England Journal of Medicine
  4. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial (2016)
    Sally E. Wenzel, Mario Castro et al. The Lancet
  5. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma (2021)
    Andrew Menzies‐Gow, Jonathan Corren et al. New England Journal of Medicine
  6. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials (2020)
    Philippe Gevaert, Theodore A. Omachi et al. Journal of Allergy and Clinical Immunology
  7. Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials (2023)
    Jonathan Corren, Andrew Menzies‐Gow et al. American Journal of Respiratory and Critical Care Medicine

Immediate Impact

11 from Science/Nature 113 standout
Sub-graph 1 of 14

Citing Papers

Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
2025 Standout
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
2024 Standout
13 intermediate papers

Works of Jonathan Corren being referenced

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study
2021
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
2020 Standout
and 7 more

Author Peers

Author Last Decade Papers Cites
Jonathan Corren 8614 4990 4455 201 10.5k
Philippe Godard 6154 4252 2010 185 8.9k
Piotr Kuna 5219 2991 2659 359 7.9k
Barbro Dahlén 4666 2967 1817 136 6.9k
Brian O’Connor 6467 4017 1793 99 8.2k
Gail M. Gauvreau 4974 2499 1905 170 6.6k
Andrew Menzies‐Gow 6264 4308 1682 154 7.5k
Parameswaran Nair 7420 5165 1689 211 9.6k
Glenis Scadding 5291 1750 5343 210 9.0k
Michael E. Wechsler 5593 4773 1200 167 8.6k
Enrico Heffler 2705 1722 1672 228 4.7k

All Works

Loading papers...

Rankless by CCL
2026